Sprint Bioscience AB - Asset Resilience Ratio
Sprint Bioscience AB (SPRINT) has an Asset Resilience Ratio of 77.81% as of September 2022. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See SPRINT working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2017)
This chart shows how Sprint Bioscience AB's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see total assets of Sprint Bioscience AB.
Liquid Assets Composition Over Time
This chart breaks down Sprint Bioscience AB's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read SPRINT liabilities breakdown for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr26.73 Million | 77.81% |
| Short-term Investments | Skr0.00 | 0% |
| Total Liquid Assets | Skr26.73 Million | 77.81% |
Asset Resilience Insights
- Very High Liquidity: Sprint Bioscience AB maintains exceptional liquid asset reserves at 77.81% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Sprint Bioscience AB Industry Peers by Asset Resilience Ratio
Compare Sprint Bioscience AB's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Dianthus Therapeutics Inc.
NASDAQ:DNTH |
Biotechnology | 63.98% |
|
Tango Therapeutics Inc
NASDAQ:TNGX |
Biotechnology | 62.24% |
|
Damora Therapeutics, Inc.
NASDAQ:DMRA |
Biotechnology | 0.00% |
|
Wecome Pharmaceutical Co Ltd
SHE:300878 |
Biotechnology | 0.67% |
|
Tectonic Therapeutic, Inc.
NASDAQ:TECX |
Biotechnology | 86.66% |
|
Relmada Therapeutics Inc
NASDAQ:RLMD |
Biotechnology | 95.25% |
|
MediWound Ltd
F:M8W |
Biotechnology | 56.04% |
Annual Asset Resilience Ratio for Sprint Bioscience AB (2016–2017)
The table below shows the annual Asset Resilience Ratio data for Sprint Bioscience AB.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2017-12-31 | 4.17% | Skr1.48 Million ≈ $159.16K |
Skr35.48 Million ≈ $3.82 Million |
-43.50pp |
| 2016-12-31 | 47.67% | Skr23.61 Million ≈ $2.54 Million |
Skr49.52 Million ≈ $5.33 Million |
-- |
About Sprint Bioscience AB
Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of drug candidates to treat cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; DCPS which is in preclinical trial for the treatment of acute myeloid leukemia; VRK1, which is in preclinical development to treat solid tumors; VPS34, a d… Read more